KAT14

Across TCGA pan-cancer cohorts, KAT14 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KAT14 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher KAT14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated KAT14 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, PDAC, and LUAD are the cancer types where KAT14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.577	0.219	<.001	13	view →
PDAC	OS	Tertile	All	0.704	0.959	.005	9	view →
LUAD	DFS	Quartile	All	0.820	0.502	.010	5	view →
LSCC	DFS	Median	II,III,IV	0.813	0.577	.022	4	view →
CCRCC	DFS	Median	All	1.000	0.497	.024	3	view →
UCEC	DFS	Median	All	1.000	0.930	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KAT14–GBM (OS)

Open the GBM breakdown →